Sterling in China
This article was originally published in The Tan Sheet
Executive Summary
Joint venture with Shanghai Meiyou Pharmaceutical Company will manufacture and market Sterling's Panadol line as well as a "range of other consumer health products" in the People's Republic of China, Sterling announces Sept. 2. The U.S. firm said it will "provide manufacturing equipment and technical expertise" while Meiyou will provide "market knowledge" and "manufacturing expertise and capability." Under the agreement, Sterling will have a 60% stake in the joint venture.